GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (NAS:CSBR) » Definitions » Cyclically Adjusted Revenue per Share

Champions Oncology (Champions Oncology) Cyclically Adjusted Revenue per Share : $2.74 (As of Jan. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Champions Oncology Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Champions Oncology's adjusted revenue per share for the three months ended in Jan. 2024 was $0.884. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.74 for the trailing ten years ended in Jan. 2024.

During the past 12 months, Champions Oncology's average Cyclically Adjusted Revenue Growth Rate was 6.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Champions Oncology was 9.40% per year. The lowest was -9.20% per year. And the median was 1.50% per year.

As of today (2024-05-14), Champions Oncology's current stock price is $4.64. Champions Oncology's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 was $2.74. Champions Oncology's Cyclically Adjusted PS Ratio of today is 1.69.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Champions Oncology was 11.40. The lowest was 0.84. And the median was 3.31.


Champions Oncology Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Champions Oncology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Cyclically Adjusted Revenue per Share Chart

Champions Oncology Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.97 2.03 2.10 2.39 2.66

Champions Oncology Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.57 2.66 2.70 2.74 2.74

Competitive Comparison of Champions Oncology's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Champions Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Champions Oncology's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Champions Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Champions Oncology's Cyclically Adjusted PS Ratio falls into.



Champions Oncology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Champions Oncology's adjusted Revenue per Share data for the three months ended in Jan. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=0.884/129.4194*129.4194
=0.884

Current CPI (Jan. 2024) = 129.4194.

Champions Oncology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201404 0.441 100.023 0.571
201407 0.328 100.520 0.422
201410 0.333 100.176 0.430
201501 0.326 98.604 0.428
201504 0.365 99.824 0.473
201507 0.324 100.691 0.416
201510 0.341 100.346 0.440
201601 0.293 99.957 0.379
201604 0.327 100.947 0.419
201607 0.373 101.524 0.475
201610 0.406 101.988 0.515
201701 0.325 102.456 0.411
201704 0.301 103.167 0.378
201707 0.458 103.278 0.574
201710 0.474 104.070 0.589
201801 0.462 104.578 0.572
201804 0.447 105.708 0.547
201807 0.493 106.324 0.600
201810 0.477 106.695 0.579
201901 0.559 106.200 0.681
201904 0.527 107.818 0.633
201907 0.580 108.250 0.693
201910 0.588 108.577 0.701
202001 0.659 108.841 0.784
202004 0.687 108.173 0.822
202007 0.671 109.318 0.794
202010 0.672 109.861 0.792
202101 0.745 110.364 0.874
202104 0.716 112.673 0.822
202107 0.840 115.183 0.944
202110 0.810 116.696 0.898
202201 0.917 118.619 1.000
202204 0.913 121.978 0.969
202207 1.016 125.002 1.052
202210 1.056 125.734 1.087
202301 0.942 126.223 0.966
202304 0.963 127.992 0.974
202307 0.930 128.974 0.933
202310 0.857 129.810 0.854
202401 0.884 129.419 0.884

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Champions Oncology  (NAS:CSBR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Champions Oncology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.64/2.74
=1.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Champions Oncology was 11.40. The lowest was 0.84. And the median was 3.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Champions Oncology Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Champions Oncology (Champions Oncology) Business Description

Industry
Traded in Other Exchanges
Address
One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
Executives
Daniel Newman Mendelson director COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR, SUITE 900, BETHESDA MD 20817
Ronnie Morris director, officer: President 855 N. WOLFE STREET, SUITE 619, BALTIMORE MD 21205
Philip P. Breitfeld director ONE UNIVERSITY PLAZA, SUITE 307, HACKENSACK NJ 07601
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Neeraj Agrawal 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Roger H Lee 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Michael Maurice Brown 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Battery Management Corp. 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
R David Tabors 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Jesse Feldman 10 percent owner ONE MARINA PARK DRIVE, SUITE 1100, BOSTON MA 02210
Joel Ackerman director, officer: Chief Executive Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Patrick J Kerins 10 percent owner
Ryan D Drant 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202
Nea 14 Gp, Ltd 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093